By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
CRL's Q1 results show resilience but underlying issues persist. The 'Pathway to Purpose' plan aims to drive margin expansion through divestments and acquisitions, but its success depends on executing deals and stabilizing the NHP supply chain. Organic revenue contraction and DSA's margin drop raise concerns about long-term growth.
Risk: The single biggest risk flagged is the potential failure of the 'Pathway to Purpose' plan to deliver expected margin expansion and growth, given the ongoing organic revenue contraction and DSA's margin drop.
Opportunity: The single biggest opportunity flagged is the potential for CRL to successfully execute its divestment and acquisition strategy, driving margin expansion and a structural re-rating of the business model.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Charles River beat its prior outlook in Q1 2026, with revenue of $996 million up 1.2% year over year, though organic revenue fell 1.5% and non-GAAP EPS declined 12% to $2.06. Management said results were slightly ahead of expectations despite margin pressure from NHP costs, stock compensation tied to the CEO transition, and mix issues.
The company reaffirmed full-year 2026 guidance for organic revenue down 0.5% to 1.5% and non-GAAP EPS of $10.80 to $11.30, while still expecting 120 to 150 basis points of margin expansion later in the year. Charles River also increased its reported revenue decline outlook because of a stronger U.S. dollar.
Portfolio reshaping and new CEO strategy are major themes, as Birgit Girshick launched the “Pathway to Purpose” plan and the company completed or advanced several divestitures and acquisitions. Management said these moves are designed to sharpen core focus, improve profitability, and strengthen its NHP supply chain and testing capabilities.
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
Charles River Laboratories International (NYSE:CRL) reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chief Executive Officer Birgit Girshick.
Girshick, who became CEO during the week of the call, said the company is entering a new phase under a strategic plan called “Pathway to Purpose,” focused on modernizing operations, strengthening its scientific portfolio, deepening client relationships and improving profitability.
“The world is changing rapidly around us. Science is advancing faster than it ever has, and our clients require greater speed, best science, and more collaboration,” Girshick said. She said Charles River plans to provide more detail on the strategy at an Investor Day in September.
First-quarter revenue rises on reported basis, declines organically
Executive Vice President and Chief Financial Officer Glenn Coleman, who joined the company in April, said Charles River reported first-quarter revenue of $996 million, up 1.2% from a year earlier. On an organic basis, revenue declined 1.5%, which Coleman said was consistent with the company’s February outlook for a low single-digit organic decline.
Non-GAAP operating margin fell 280 basis points year over year to 16.3%. Non-GAAP earnings per share declined 12% to $2.06, though Coleman said EPS exceeded the company’s prior outlook for a high-teens decline because of better-than-expected operating performance in the Manufacturing and Research Models and Services segments.
Management attributed the margin decline to several discrete factors, including lower non-human primate, or NHP, third-party revenue in the RMS segment, the timing of stock compensation expense tied to the CEO transition, and higher NHP sourcing costs and study starts in the Discovery and Safety Assessment segment.
Charles River also repurchased approximately $200 million of shares during the quarter under a $1 billion stock repurchase authorization approved last October. Coleman said net leverage was 2.6 times at quarter-end.
Segment performance mixed as Manufacturing margin improves
In Discovery and Safety Assessment, or DSA, revenue was $597 million, down 1.4% organically from the prior-year quarter. Coleman said lower revenue for discovery services, partly due to prior site consolidation activities, was partially offset by stable safety assessment revenue. DSA operating margin declined 290 basis points to 21.0%, primarily because of higher study-related direct costs, including NHP sourcing costs and study starts.
Research Models and Services revenue was $208 million, down 5.5% organically. The decline reflected lower sales of small and large models, as well as research model services. Management said small model revenue was pressured by lower North American volume but partially offset by solid growth in China. RMS operating margin fell 240 basis points to 24.7%, largely due to unfavorable revenue mix from NHP shipment timing and lower small model sales in North America.
Manufacturing revenue was $191 million, up 2.9% organically, driven by growth in the Microbial Solutions business, including the Endosafe and Celsis manufacturing quality control testing platforms. Manufacturing operating margin improved 280 basis points to 25.9%, which Coleman attributed to revenue leverage and cost savings.
Guidance reaffirmed, with margin expansion expected later in 2026
Charles River reaffirmed its 2026 outlook for an organic revenue decline of 0.5% to 1.5% and non-GAAP earnings per share of $10.80 to $11.30, representing 5% to 10% growth over 2025. The guidance includes approximately $0.10 per share of earnings accretion from divestitures.
On a reported basis, Coleman said the company reduced its revenue outlook by 50 basis points to a decline of 4.0% to 5.5%, citing less favorable foreign exchange rates due to the recent strengthening of the U.S. dollar. He said the FX headwind to earnings is expected to be essentially offset by accretion from share repurchases.
The company continues to expect operating margin expansion of about 120 to 150 basis points in 2026, with most of the improvement coming in the second half of the year. Coleman said the second-half operating margin is expected to be more than 500 basis points higher than the first-half level, with more than half of the improvement driven by completed acquisitions and divestitures, along with the planned sale of certain European discovery sites.
For the second quarter, Coleman said Charles River expects reported revenue to decline at a mid- to high-single-digit rate year over year, primarily due to divestitures. Organic revenue is projected to decline at a low-single-digit rate, similar to the first quarter. EPS is expected to increase at least 30% sequentially from the first-quarter level of $2.06.
Strategic transactions reshape portfolio
Girshick said Charles River completed the divestiture of its CDMO and Cell Solutions businesses on May 6 and expects to complete the planned sale of certain European discovery sites later in May. She said the transactions are intended to refine the company’s portfolio around core competencies and improve future operating margins.
The company also acquired assets of K.F. Cambodia earlier this year, now called Charles River Cambodia, which Girshick said strengthens and secures the NHP supply chain for safety assessment operations. Combined with Noveprim, in which Charles River acquired a controlling stake in 2023, the company expects to internally source most of its future NHP supply requirements for DSA.
In April, Charles River completed the acquisition of PathoQuest, adding an in vitro next-generation sequencing platform for quality control testing of biologic drugs. Girshick described the acquisition as part of the company’s effort to expand New Approach Methodologies, or NAMs.
Management cites stable demand with pockets of improvement
Girshick said the overall biopharma demand environment stabilized last year, and Charles River is seeing “pockets of improvement” among both global biopharmaceutical and small and mid-sized biotechnology clients. She said revenue from global biopharmaceutical clients increased in the first quarter, while revenue from small and mid-sized biotech clients declined, primarily reflecting softer DSA booking activity last summer and the typical lag between bookings and revenue.
DSA net book-to-bill was 1.04 times in the quarter, and backlog increased slightly on a sequential basis to $1.92 billion. Net bookings totaled $622 million. Girshick said biotech net bookings and net book-to-bill over the past two quarters were at their highest levels in more than two years.
During the question-and-answer session, Girshick said proposal volumes were up in the high single digits year over year across both global biopharmaceutical and biotech client segments. Coleman added that proposals had increased sequentially for three consecutive quarters.
Girshick also discussed artificial intelligence, saying she expects AI to support the industry over time by improving the speed and efficiency of early discovery. However, she said the number of AI-assisted drug programs remains small and that any impact on Charles River’s preclinical testing business is still in early stages.
“It’s very early days,” Girshick said. “There’s so few programs in the pipeline that are AI assisted.”
She said Charles River is also applying AI and machine learning internally, including in its Virtual Control Groups program for safety assessment studies, which is intended to preserve scientific integrity while reducing reliance on animal models.
About Charles River Laboratories International (NYSE:CRL)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Four leading AI models discuss this article
"The projected 500 basis point margin expansion in the second half is overly optimistic and assumes near-perfect execution on site divestitures and NHP cost containment."
CRL is effectively a 'show me' story under new CEO Girshick. While the 1.04 book-to-bill ratio in DSA suggests a potential bottoming in biotech demand, the 280 basis point margin contraction is alarming. Management is banking on a massive second-half margin recovery—500 bps higher than H1—which relies heavily on divestiture execution and NHP supply chain stabilization. With organic revenue still negative, the 'Pathway to Purpose' plan feels like a defensive pivot to appease shareholders rather than a growth catalyst. I remain skeptical that they can hit the high end of their $10.80-$11.30 EPS guidance without further cost-cutting that could impair long-term service quality.
If the biotech funding environment accelerates in H2 2026, the current backlog and increased proposal volumes could lead to an operating leverage explosion that makes the current valuation look like a massive entry point.
"Securing ~100% internal NHP supply via Cambodia/Noveprim de-risks DSA margins, enabling guided 500bps+ H2 expansion and EPS growth despite flat-to-down organic revenue."
CRL's Q1 beat low expectations amid organic -1.5% revenue decline, but reaffirmed FY organic -0.5% to -1.5% and EPS growth of 5-10% to $10.80-$11.30 signals stabilization. Key positives: Manufacturing margin +280bps to 25.9% on Microbial Solutions growth; portfolio reshaping (CDMO divestiture, Cambodia/Noveprim for NHP self-supply, PathoQuest for NAMs) targets 120-150bps FY margin expansion, mostly H2. Backlog at $1.92B, biotech bookings at 2-yr highs, proposals +high single-digits YoY. $200M buybacks at 2.6x net leverage accretive vs. FX drag. New CEO's 'Pathway to Purpose' details in Sept could catalyze re-rating from depressed multiples.
Biopharma/biotech funding winter persists, with DSA bookings lag risking H2 organic miss deeper than guided low-single-digits; NHP self-sourcing may not fully offset elevated costs if China export bans recur.
"CRL is guiding to full-year organic revenue decline despite claiming demand stabilization, which suggests management lacks conviction in a near-term recovery and is relying on financial engineering (divestitures, buybacks) to hit EPS targets."
CRL's Q1 miss on organic revenue (-1.5%) and 12% EPS decline mask a deteriorating operational picture. Yes, management reaffirmed FY26 guidance, but that guidance itself implies only 5-10% EPS growth on a base that's already contracting organically. The 280 bps margin compression is attributed to 'discrete' items (NHP costs, CEO transition stock comp), yet the company still expects 120-150 bps expansion in H2—a claim dependent on divestitures and cost cuts, not demand recovery. DSA margin fell 290 bps despite being the core business. Most concerning: organic revenue guidance of -0.5% to -1.5% for FY26 signals ongoing contraction, not stabilization. The 'pockets of improvement' language is corporate-speak for uneven demand.
The DSA book-to-bill of 1.04x and highest biotech net bookings in 2+ years suggest demand is genuinely inflecting; if that converts to revenue in Q2-Q3, the H2 margin expansion thesis becomes credible, and the stock could re-rate on forward visibility.
"The most important claim: 2026 earnings upside rests on aggressive portfolio reshaping delivering material margin uplift, which is not guaranteed and could be eroded by FX, NHP costs, and ongoing organic weakness."
CRL's Q1 shows resilience on a headline basis but underlying dynamics raise questions: revenue +1.2% to $996m, organic -1.5%, non-GAAP EPS -12% to $2.06. The real message is the strategic pivot under Birgit Girshick: Pathway to Purpose plus divestitures and select acquisitions aimed at margin expansion and a tighter NHP-focused portfolio. The guidance assumes 120-150 bps margin lift in 2026, largely driven by the second-half impact of deals and site sales, which is a big assumption. Near-term margin pressure from NHP costs, stock comp tied to the CEO transition, and FX headwinds persist. The backlog and net bookings look solid, but whether demand sustains across DSA/NAMs remains a key risk.
The strongest counter: the margin improvement is highly contingent on deal timing and execution; if divestitures close later or fail to deliver anticipated synergies, EPS could miss guidance. Additionally, the organic revenue decline suggests structural softness that acquisitions alone may not fix.
"CRL's margin expansion is a structural shift via divestiture rather than just a demand-led recovery."
Claude, you’re fixated on the organic revenue contraction, but you’re ignoring the capital allocation shift. CRL is pivoting from a volume-heavy CRO model to a higher-margin specialty services provider. The 280 bps margin compression isn't just 'discrete' noise; it’s the cost of unwinding the NHP supply chain dependency. If they successfully divest the low-margin CDMO assets, the EPS growth isn't just 'corporate-speak'—it’s a structural re-rating of the business model, provided they don't overpay for further NAM acquisitions.
"CDMO divestiture won't fix DSA margin erosion, which signals persistent core demand issues."
Gemini, your structural re-rating via CDMO divestiture sounds neat, but it's speculative—management pegs only part of the 120-150bps expansion to it, with bulk from NHP fixes and cost cuts. Flaw: Ignores DSA's 290bps margin drop despite 1.04 book-to-bill; that's core weakness, not pivot progress. If biotech winter lingers, no leverage explosion.
"DSA's 290bps margin drop despite 1.04x book-to-bill suggests the backlog isn't converting at historical rates or mix is deteriorating—a red flag Gemini's structural re-rating doesn't address."
Grok flags the DSA margin collapse despite strong book-to-bill—that's the real tell. A 1.04x ratio should translate to pricing power or volume leverage, not 290bps erosion. Either DSA is losing mix (lower-margin work), or the backlog isn't converting at expected rates. Neither scenario supports the H2 margin recovery thesis without external tailwinds. The NHP fixes and cost cuts are one-time; they don't fix structural DSA weakness if biotech bookings don't sustain.
"Divestitures alone won't guarantee margin uplift; DSA weakness and uncertain H2 demand imply EPS risk despite Pathway to Purpose."
Grok's belief that 120-150bps of margin uplift largely from NHP fixes and cost cuts overlooks two headwinds. First, DSA margin collapse (290bps) signals ongoing mix and pricing pressure even if divestitures close; second, backlog quality and biotech demand remain uncertain in H2, so the implied leverage is not guaranteed to flow through. If CDMO divestitures close late or at modest multiples, EPS downside risk persists despite 'Pathway to Purpose' rhetoric.
CRL's Q1 results show resilience but underlying issues persist. The 'Pathway to Purpose' plan aims to drive margin expansion through divestments and acquisitions, but its success depends on executing deals and stabilizing the NHP supply chain. Organic revenue contraction and DSA's margin drop raise concerns about long-term growth.
The single biggest opportunity flagged is the potential for CRL to successfully execute its divestment and acquisition strategy, driving margin expansion and a structural re-rating of the business model.
The single biggest risk flagged is the potential failure of the 'Pathway to Purpose' plan to deliver expected margin expansion and growth, given the ongoing organic revenue contraction and DSA's margin drop.